<DOC>
	<DOCNO>NCT02483975</DOCNO>
	<brief_summary>Inhaled corticosteroid ( ICS ) number know class effect include hypothalamic-pituitary-adrenocortical ( HPA ) axis suppression . Although safety inhale Fluticasone Furoate ( FF ) HPA axis adult adolescent asthmatic patient establish , important ass risk suppression child establish whether medicine safely use young population . This study aim evaluate effect inhale FF HPA axis child 5-11 year age ( inclusive ) persistent asthma compare placebo . Approximately 143 subject enrol . Subjects enter 7 14 day run-in period oral montelukast 4 milligram ( mg ) ( 5 year old subject ) 5 mg ( 6-11 year old subject ) daily . Eligible subject randomize receive once-daily FF inhalation powder 50 microgram ( mcg ) once-daily placebo inhalation powder morning via ELLIPTAâ„¢ inhaler 42 day . Subjects continue receive open label montelukast treatment period . All subject provide albuterol/salbutamol inhalation aerosol , use need treat acute asthma symptom throughout study . ELLIPTA register trademark GlaxoSmithKline group company .</brief_summary>
	<brief_title>Effect Fluticasone Furoate Inhalation Powder Hypothalamic-pituitary-adrenocortical Axis Children Aged 5-11 Years With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Informed consent : Written inform consent least one parent/care giver accompany informed assent subject ( subject able provide assent ) prior admission study . If applicable , subject must able willing give assent take part study accord local requirement . The study investigator accountable determine child 's capacity assent participation research study , take consideration standard set responsible Independent Ethics Committee ( IEC ) /Institutional Review Board ( IRB ) . Subject legal guardian understands must comply study medication study assessment . Age : 511 year ( inclusive ) Visit 1 . Weight : Subjects must weigh least 17 kilogram ( kg ) . Gender : Male premenarchial female . Premenarchial female define female yet begin menses . Diagnosis asthma : Subjects must diagnosis asthma documented medical history least 6 month prior Visit 1 . Childhood Asthma Control Test ( CACT ) : Subjects must CACT score &gt; 19 . Asthma Therapy Prior Visit 1 : Subjects eligible use noncorticosteroid controller and/or shortacting beta2agonist ( SABA ) bronchodilator alone least 4 week prior Visit 1 . Ability use Dry Powder Inhalers : Subjects must demonstrate ability use ELLIPTA inhaler supervision parents/caregiver . SABA : All subject must able replace current SABA treatment albuterol/salbutamol aerosol inhaler Visit 1 use need duration study . Albuterol/salbutamol meter dose inhaler ( MDI ) administer without spacer , use determine investigator . The use nonuse spacer consistent individual subject throughout study . Peak Flow Meter/Daily Diary Compliance : A subject must able use studyprovided peak flow meter subject/caregiver must able maintain electronic diary record . History LifeThreatening Asthma : Subjects history lifethreatening asthma define protocol asthma episode require intubation , hypercapnea require noninvasive ventilatory support , respiratory arrest , hypoxic seizure asthmarelated syncopal episode ( ) . Asthma Exacerbation : Subjects history asthma exacerbation require use systemic corticosteroid ( tablet , suspension , injection ) least 3 day depot corticosteroid injection ( within 3 month ) require hospitalization asthma ( within 6 month ) prior screen . Respiratory Infection : Culturedocumented suspect bacterial viral infection upper low respiratory tract , sinus middle ear resolve within 4 week Visit 1 lead change asthma management opinion Investigator , expect affect subject 's asthma status subject 's ability participate study . Oropharyngeal Examination : A subject eligible runin he/she clinical visual evidence candidiasis Visit 1 . Concurrent Disease : Any significant abnormality medical condition identify screen medical assessment ( include serious psychological disorder congenital metabolic disorder ) likely interfere conduct study affect safety patient . Allergies/Intolerance : Drug Allergy/Intolerance : Any adverse reaction include immediate delay hypersensitivity Leukotriene receptor antagonist ( LTRA ) , intranasal , inhale , systemic corticosteroid therapy . Known suspected sensitivity/intolerance constituent powder inhaler ( i.e . lactose ) montelukast ( e.g . phenylalanine ) . Milk Protein Allergy : History severe milk protein allergy . Corticosteroid Use : Administration systemic , oral , depot corticosteroid within 12 week Visit 1 prohibit study . Use ICS prohibit 8 week prior Visit 1 study . Use intranasal corticosteroid prohibit 4 week prior Visit 1 study . Use dermatological/topical corticosteroid 8 week prior Visit 1 study . Concomitant Medication : Use prescription overthecounter medication would significantly affect course asthma HPA axis system subject . In addition , use potent cytochrome P450 3A4 ( CYP3A4 ) inhibitor within 4 week Visit 1 study ( e.g. , Clarithromycin , atazanavir , indinavir , itraconazole , ketoconazole , nefazadone , nelfinavir ; ritonavir ; saquinavir ; telithromycin , troleandomycin , voriconazole , mibefradil , cyclosporine ) . Tobacco/Marijuana Use : Present use tobacco marijuana product . Affiliation Investigator 's Site : A subject eligible study he/she immediate family member participate investigator , subinvestigator , study coordinator , employee participate investigator . Parental/ Guardian Factors : Parent Guardian history psychiatric disease , intellectual deficiency , substance abuse condition ( e.g . inability read , comprehend write ) may affect : validity consent participate study , adequate supervision subject study , compliance subject study medication study procedure ( e.g . completion daily diary , attend schedule clinic visit ) subject safety wellbeing . Children Care : Children ward government state eligible participation study . Clinically significant obesity : Defined great 98th percentile .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Fluticasone Furoate</keyword>
	<keyword>Asthma</keyword>
	<keyword>HPA axis</keyword>
	<keyword>Children</keyword>
	<keyword>Inhaled corticosteroid</keyword>
</DOC>